|
|
Article: DUSA Pharmaceuticals Reviews and Updates Progress at Annual Meeting.
- Article from:
- Business Wire
- Article date:
- June 15, 2000
CopyrightCOPYRIGHT 2000 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors, Health/Medical Writers
WILMINGTON, Mass.--(BUSINESS WIRE)--June 15, 2000
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) held its Annual Meeting today at the Company's new Wilmington, Mass. headquarters. Dr. Geoffrey Shulman, President and CEO, and the rest of the management team, reviewed the accomplishments of the past year, and updated shareholders on the outlook for the remainder of this year.
Dr. Shulman stated, "1999 was a year of tremendous achievement for DUSA. In December, following a multi-year clinical trial development program, the Company received FDA approval for the Levulan(R) (aminolevulinic acid HCl, ALA) ...
Related newspaper, magazine, and journal articles:
|
|
Article: DUSA Pharmaceuticals Reports First Quarter ...
Business Wire;
May 10, 2000 ;
700+ words
... ... HEALTHWIRE)--May 10, 2000 DUSA Pharmaceuticals, Inc. (NASDAQ/NMS ... dermatology marketing partner, Schering AG Germany and its US affiliate ... marketing expertise, and Schering AG's strength in dermatology ... from the doctors. DUSA and Schering AG are also developing ...
|
|